• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Pressure BioSciences' New Consumer Products Unit Continues Long Sales Relationship with Dominant U.S. Retailer, Launching 2024 with Quarter Million Dollar Shipment in January

    1/16/24 8:47:45 AM ET
    $PBIO
    Get the next $PBIO alert in real time by email

    SOUTH EASTON, Mass., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a pioneer in the development and distribution of broadly enabling pressure-based instruments, consumables, and specialty process development and testing services across global industries, including nutraceuticals, food and beverage, health and wellness, cosmetics, biotherapeutics, and more, announced on January 11, 2024 the execution of a definitive agreement (the "Asset Purchase Agreement", or "APA") to acquire renowned natural health and wellness leader Uncle Bud's. Today, the Company announced the beginning of summer season order filling with one of the globe's leading retailers and a long-standing partner for Uncle Bud's, with the shipment of a significant $252,000 order for its popular Sunburn Soother.

    Upon transaction closing (expected on or before January 19), the combined company plans to become a leading provider of topicals and other consumer products containing oil-based active ingredients (including many vitamins, pain relievers, nutraceutical supplements, and cosmeceuticals). The Company plans to leverage PBIO's patented UltraShearTM technology platform for nanoemulsification processing to improve many of these products, delivering unparalleled speed of action and effective payload bioavailability, in "green label" preservative-free products with unprecedented long-term stability.

    Bruno Schiavi, President of PBIO's newly created Consumer Products Business Unit, commented: "With over 9 million products sold in the last five years and a vibrant online community of over 865,000 members, Uncle Bud's is more than a well-known, nationwide, family values brand: it's a lifestyle. Now, the merger of Uncle Bud's with PBIO's revolutionary nanoemulsions technology represents not just a business transaction – it is the birth of a health and wellness revolution."

    Mr. Schiavi continued: "UltraShear presents a tremendous opportunity to make some of our already successful high-performance products even better, as well as to develop and commercialize new, breakthrough consumer products that depend on oil-soluble active ingredients.  The key to success in the consumer products field is knowing what the customer wants, having the capability to create that product and the ability to get it to the consumer at a fair price, and then to execute, execute, execute! We have always been good at this; now with the technical assets and expertise of PBIO, we are clearly poised for exciting new growth ahead!"

    John Hollister, PBIO's Director of Marketing and Sales, added: "We are very excited to watch the seasoned commercial team at Uncle Bud's start applying our innovative UltraShear processing to some of their existing products, as well as the new products they are planning to develop.  The fact that they already have highly-acclaimed products on the shelves of some of the biggest retailers in the U.S. is very exciting, as it accelerates our timeline for accessing these discerning customers with PBIO's growing list of nanoemulsified products. We have been particularly impressed by their consumer insights, and we know that this will translate into many new consumer product successes for us in 2024 and beyond."

    Ric Schumacher, President and CEO of PBIO, added: "As mentioned in the January 11th press release, we believe the integration of Uncle Bud's into PBIO will be immediately accretive and a major accelerator to revenue growth, as evidenced by this $252,000 shipment only days after executing the APA. We expect dramatic growth in orders from our newly-formed Consumer Products Business Unit in the coming weeks and months, some far larger than the one just announced, concomitant with an equally impressive growth in orders from the core PBIO product line, specifically from UltraShear."

    About Uncle Bud's

    Officially launched in September 2018 with one hero product, Uncle Bud's has experienced unequivocal growth. As a leader in the Hemp and CBD space, Uncle Bud's takes pride in being Made in America, GMO Free, Cruelty Free and Leaping Bunny Certified. The full range includes Hemp & CBD products for pain relief, skincare, personal care, and even pet care – all retailing under $45.To learn more about Uncle Bud's visit unclebudshemp.com as well as their associated Instagram: @UncleBuds_Hemp; Facebook: @UncleBuds_Hemp and Twitter: @UncleBuds_Hemp.

    About Pressure BioSciences, Inc.

    Pressure BioSciences, Inc. (OTCQB:PBIO) is a global leader in providing innovative, broadly enabling, high pressure-based solutions for a range of industries, including biotechnology, pharmaceutical, nutraceutical, cosmeceutical, and agrochemical, as well as food and beverage manufacturing. Our products utilize both constant and alternating pressure. Our patented enabling technology platform, Pressure Cycling Technology (PCT), utilizes alternating cycles of pressure to control bio-molecular interactions (such as cell lysis and biomolecule extraction) safely and reproducibly. PCT-based products are beginning to be widely used for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterrorism applications. We have recently expanded our market opportunities with the acquisition of the BaroFold™ patented technology platform, allowing us to enter the bio-pharma contract services and GMP manufacturing equipment sector. We have also developed the scalable and high-efficiency pressure-based UltraShear Technology™ (UltraShear™) platform, which allows for the creation of stable nanoemulsions of otherwise immiscible fluids. It also allows for the preparation of higher quality, homogenized, extended shelf-life or room temperature-stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. Our commitment to innovation and cutting-edge technology has established PBIO as a leader in the high-pressure industry, providing unique and effective solutions to our customers.

    Forward Looking Statements

    This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2022, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

    For more information about PBI, Uncle Bud's, and this press release, please click on the following website links:

    http://www.pressurebiosciences.com     www.unclebudshemp.com

    Please visit us on Facebook, LinkedIn, and Twitter.

    Press Contacts: 
    Richard T. Schumacher, President & CEO(508) 230-1828 (T)
    John B. Hollister, Director of Sales and Marketing(805) 908-5719 (T)
    Bruno Schiavi, President, Consumer Products Business Unit(508) 230-1828 (T)



    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/cbb769b1-a64e-43ab-8dde-f94c7ba86b3b



    Primary Logo

    Get the next $PBIO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PBIO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PBIO
    SEC Filings

    See more
    • SEC Form 10-Q filed by Pressure BioSciences, Inc.

      10-Q - PRESSURE BIOSCIENCES INC (0000830656) (Filer)

      2/7/25 5:30:43 PM ET
      $PBIO
    • SEC Form 10-Q filed by Pressure BioSciences, Inc.

      10-Q - PRESSURE BIOSCIENCES INC (0000830656) (Filer)

      9/6/24 5:17:19 PM ET
      $PBIO
    • SEC Form NT 10-Q filed by Pressure BioSciences, Inc.

      NT 10-Q - PRESSURE BIOSCIENCES INC (0000830656) (Filer)

      8/19/24 5:20:09 PM ET
      $PBIO

    $PBIO
    Financials

    Live finance-specific insights

    See more
    • Uncle Bud's to Launch New Premium Health and Wellness Products Leveraging Pressure BioSciences UltraShear Processing for Revolutionary Product Effectiveness

      Multi-Patented Nanoemulsification Platform Enables Wide-Range of Best-in-Class Health and Wellness Products - Revenue Impact of $5 Million in 2024 Anticipated with Further Acceleration in 2025 & Beyond Pressure BioSciences February 5th Investor Call to Discuss Impact of Recent Uncle Bud's Acquisition SOUTH EASTON, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a pioneer in the development and distribution of broadly enabling pressure-based instruments, consumables, and specialty process development and testing services across global industries, including health and wellness, nutraceuticals, food and beverage, cosmetics, biothe

      2/5/24 8:23:04 AM ET
      $PBIO
    • Pressure BioSciences, Inc. Reports Q3 2023 Financial Results, Provides Business Update, and Offers Guidance for Remainder of 2023

      Investor Call Scheduled for Tuesday, November 21, 2023 at 4:30 p.m. ETSOUTH EASTON, MA / ACCESSWIRE / November 21, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide biotechnology, biotherapeutics, nutraceuticals, cosmeceuticals, agriculture, and food & beverage industries, today reported financial results for the third quarter ended September 30, 2023, provided a business update, and offered limited guidance for expected achievements through the remainder of 2023.Financial Highlights: Q3 2023 vs. Q3 2022 (rounded to nearest

      11/21/23 9:28:00 AM ET
      $PBIO
    • Pressure BioSciences, Inc. to Discuss Third Quarter 2023 Financial Results and Provide Business Update

      Conference Call Scheduled for Tuesday, November 21 at 4:30pm ETSOUTH EASTON, MA / ACCESSWIRE / November 20, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" and the "Company") today announced that the Company will host a teleconference to discuss its Third Quarter 2023 financial results and to provide a business update. Anyone interested may listen to the teleconference either live (by telephone) or through a replay (by telephone or via a link on the Company's website) approximately one day after the teleconference.The teleconference will include a Company presentation followed by a Question & Answer period.Date: Tuesday, November 21, 2023. Time: 4:30 PM Eastern Time (ET).To attend thi

      11/20/23 9:15:00 AM ET
      $PBIO

    $PBIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pressure BioSciences, Inc. to Host Business and Financial Update on Thursday, June 20th at 4:30pm ET

      CANTON, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" and the "Company") today announced that the Company will host a teleconference to update investors and other stakeholders in the Company on a number of business and financial topics. The teleconference is scheduled for Thursday, June 20, 2024 at 4:30pm ET. Topics to be discussed include: FY 2023 financial and business results.FY 2024 financial and business outlook.Status of Company's relocation to its new manufacturing facility.Status of Company's new Joint Venture Program.Update on Uncle Bud's Health and WellnessProduct expansion – expected Q3/Q4 2024 release of new nanoemulsified products, i

      6/18/24 8:16:05 AM ET
      $PBIO
    • Pressure BioSciences, Inc. to Host Business and Financial Update on Wednesday, June 19th at 4:30pm ET

      SOUTH EASTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" and the "Company") today announced that the Company will host a teleconference to update investors and other stakeholders in the Company on a number of business and financial topics. The teleconference is scheduled for Wednesday, June 19, 2024 at 4:30 PM ET. The topics to be discussed include but are not limited to: FY 2023 financial and business results.FY 2024 financial and business outlook.Status of Company's relocation to its new manufacturing facility.Update on Uncle Bud's Health and WellnessProduct expansion – expected Q3/Q4 2024 commercial release of new nanoemulsified products: N

      6/13/24 10:13:34 AM ET
      $PBIO
    • Uncle Bud's Health and Wellness to Expand New Premium Collection with Novel Products for Sleep, Memory, Pain, Immunity, Feminine Hygiene, and Sexual Wellness

      SOUTH EASTON, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a leading innovator in high-pressure nanotechnology and a pioneer in the development of novel, broadly-enabling, pressure-based instruments and nanoemulsion products and services for the health & wellness, food & beverage, nutraceutical, cosmeceutical, and other industries, today revealed that its wholly-owned Uncle Bud's Health & Wellness direct-to-consumer ("DTC") subsidiary ("Uncle Bud's") has announced an expansion of products and categories in 2024 to its recently formed "Premium Collection" of state-of-the-art nanoemulsified products. Premium Collection products

      4/11/24 10:52:23 AM ET
      $PBIO

    $PBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Pressure BioSciences, Inc. (Amendment)

      SC 13G/A - PRESSURE BIOSCIENCES INC (0000830656) (Subject)

      7/30/21 2:54:00 PM ET
      $PBIO
    • SEC Form SC 13G filed by Pressure BioSciences, Inc.

      SC 13G - PRESSURE BIOSCIENCES INC (0000830656) (Subject)

      7/16/21 2:44:13 PM ET
      $PBIO

    $PBIO
    Leadership Updates

    Live Leadership Updates

    See more
    • Uncle Bud's Health & Wellness Experiencing Powerful Growth One Month Following Acquisition by Pressure BioSciences, Inc.

      SOUTH EASTON, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a pioneer in the development and distribution of broadly enabling pressure-based instruments, consumables, and specialty process development and testing services across global industries, including health and wellness, nutraceuticals, food and beverage, cosmetics, biotherapeutics, and more, is excited to announce promising early financial results from its January 19, 2024 acquisition of Uncle Bud's Health & Wellness ("UB"). Key highlights from Uncle Bud's first month following its acquisition by PBIO include: Amazon Business Rapid Growth: Amazon sales have surged, inc

      2/26/24 9:06:01 AM ET
      $PBIO

    $PBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Peterson Jeffrey N acquired $1,670 worth of shares (59,652 units at $0.03), increasing direct ownership by 72% to 142,084 units (SEC Form 4)

      4 - PRESSURE BIOSCIENCES INC (0000830656) (Issuer)

      9/30/24 4:05:23 PM ET
      $PBIO
    • Director Urdea Michael S acquired $404 worth of shares (14,429 units at $0.03), increasing direct ownership by 44% to 47,588 units (SEC Form 4)

      4 - PRESSURE BIOSCIENCES INC (0000830656) (Issuer)

      9/30/24 4:05:20 PM ET
      $PBIO
    • President, CEO Schumacher Richard T acquired $641 worth of shares (22,878 units at $0.03), increasing direct ownership by 38% to 82,967 units (SEC Form 4)

      4 - PRESSURE BIOSCIENCES INC (0000830656) (Issuer)

      9/30/24 4:05:21 PM ET
      $PBIO